Studies of patients with congenital amegakaryocytic thrombocytopenia (CAMT) point to the essential role of c-mpl+ HSC subsets in maintaining human long-term hematopoiesis in vivo. The gene discussed is MPL; the disease is congenital amegakaryocytic thrombocytopenia.